Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing
- Agreement with Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) for the manufacturing of CAR-T therapies using Lakhesys Benchtop Cell FactoryTM
- Partnership to demonstrate the ability of Astraveus’ technology to deliver reduced costs and increased efficiency in CAR-T manufacturing
Paris, France, 6 May 2025 – Astraveus SAS (“Astraveus” or the “Company”), the benchtop cell factory company, today announces that it has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) to evaluate The Lakhesys Benchtop Cell FactoryTM for the manufacturing of CAR-T therapies.
